Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.

ABSTRACT

BACKGROUND: Patients with schizophrenia (SZ) or bipolar disorder (BD) may have increased risk of complications from prescribed opioids, including opioid-induced respiratory depression. We compared prescription opioid pain medication dispensing for patients with SZ or BD versus controls over 5 years to assess dispensing trends. METHODS: This retrospective, observational study analysed US claims data from the IBM® MarketScan® Commercial and Multi-State Medicaid databases for individuals aged 18-64 years with prevalent SZ or BD for years 2015-2019 compared with age- and sex-matched controls. Baseline characteristics, comorbidities, and medication use were assessed. Proportions of individuals dispensed prescription opioids chronically (ie, ≥70 days over a 90-day period or ≥ 6 prescriptions annually) or nonchronically (≥1 prescription, chronic definition not met) were assessed. RESULTS: In 2019, the Commercial and Medicaid databases contained records for 4773 and 30,179 patients with SZ and 52,780 and 63,455 patients with BD, respectively. Patients with SZ or BD had a higher prevalence of comorbidities, including pain, versus controls in each analysis year. From 2015 to 2019, among commercially insured patients with SZ, chronic opioid-dispensing proportions decreased from 6.1% (controls 2.7%) to 2.3% (controls 1.2%) and, for patients with BD, from 11.4% (controls 2.7%) to 6.4% (controls 1.6%). Chronic opioid dispensing declined in Medicaid-covered patients with SZ from 15.0% (controls 14.7%) to 6.7% (controls 6.0%) and, for patients with BD, from 27.4% (controls 12.0%) to 12.4% (controls 4.7%). Among commercially insured patients with SZ, nonchronic opioid dispensing decreased from 15.5% (controls 16.4%) to 10.7% (controls 11.0%) and, for patients with BD, from 26.1% (controls 17.5%) to 20.0% (controls 12.2%). In Medicaid-covered patients with SZ, nonchronic opioid dispensing declined from 22.5% (controls 24.4%) to 15.1% (controls 12.7%) and, for patients with BD, from 32.3% (controls 25.9%) to 24.6% (controls 13.6%). CONCLUSIONS: The proportions of individuals dispensed chronic or nonchronic opioid medications each year were similar between commercially and Medicaid-insured patients with SZ versus controls and were higher for patients with BD versus controls. From 2015 to 2019, the proportions of individuals who were dispensed prescription opioids chronically or nonchronically decreased for patients with SZ or BD and controls.